Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun;31(6):3758-3768.
doi: 10.1245/s10434-024-15131-0. Epub 2024 Mar 7.

Towards Equal Access to Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy and Survival in Patients with Isolated Colorectal Peritoneal Metastases: A Nationwide Population-Based Study

Roos G F M van der Ven  1   2   3 , Teun B M van den Heuvel  4   5 , Koen P B Rovers  5 , Simon W Nienhuijs  5 , Djamila Boerma  6 , Wilhelmina M U van Grevenstein  7 , Patrick H J Hemmer  8 , Niels F M Kok  9 , Eva V E Madsen  10 , Philip de Reuver  11 , Jurriaan B Tuynman  12 , Felice N van Erning  13   5 , Ignace H J T de Hingh  13   4   5
Affiliations

Towards Equal Access to Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy and Survival in Patients with Isolated Colorectal Peritoneal Metastases: A Nationwide Population-Based Study

Roos G F M van der Ven et al. Ann Surg Oncol. 2024 Jun.

Abstract

Background: Before 2016, patients with isolated synchronous colorectal peritoneal metastases (PMCRC) diagnosed in expert centers had a higher odds of undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) and better overall survival (OS) than those diagnosed in referring centers. Nationwide efforts were initiated to increase awareness and improve referral networks.

Methods: This nationwide study aimed to evaluate whether the between-center differences in odds of undergoing CRS-HIPEC and OS have reduced since these national efforts were initiated. All patients with isolated synchronous PMCRC diagnosed between 2009 and 2021 were identified from the Netherlands Cancer Registry. Associations between hospital of diagnosis and the odds of undergoing CRS-HIPEC, as well as OS, were assessed using multilevel multivariable regression analyses for two periods (2009-2015 and 2016-2021).

Results: In total, 3948 patients were included. The percentage of patients undergoing CRS-HIPEC increased from 17.2% in 2009-2015 (25.4% in expert centers, 16.5% in referring centers), to 23.4% in 2016-2021 (30.2% in expert centers, 22.6% in referring centers). In 2009-2015, compared with diagnosis in a referring center, diagnosis in a HIPEC center showed a higher odds of undergoing CRS-HIPEC (odds ratio [OR] 1.64, 95% confidence interval [CI] 1.02-2.67) and better survival (hazard ratio [HR] 0.80, 95% CI 0.66-0.96). In 2016-2021, there were no differences in the odds of undergoing CRS-HIPEC between patients diagnosed in HIPEC centers versus referring centers (OR 1.27, 95% CI 0.76-2.13) and survival (HR 1.00, 95% CI 0.76-1.32).

Conclusion: Previously observed differences in odds of undergoing CRS-HIPEC were no longer present. Increased awareness and the harmonization of treatment for PMCRC may have contributed to equal access to care and a similar chance of survival at a national level.

Keywords: Cytoreductive surgery; HIPEC; Network; Referrals; Treatment variation.

PubMed Disclaimer

Conflict of interest statement

Roos G.F.M. van der Ven, Teun B.M. van den Heuvel, Koen P.B. Rovers, Simon W. Nienhuijs, Djamila Boerma, Wilhelmina M.U. van Grevenstein, Patrick H.J. Hemmer, Niels F.M. Kok, Eva V.E. Madsen, Philip de Reuver, Jurriaan B. Tuynman, Felice N. van Erning, Ignace H.J.T. de Hingh declare they have no conflicts of interest to report.

Figures

Fig. 1
Fig. 1
Proportion of patients who underwent cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021;14(10):101174. doi: 10.1016/j.tranon.2021.101174. - DOI - PMC - PubMed
    1. Lurvink RJ, Bakkers C, Rijken A, et al. Increase in the incidence of synchronous and metachronous peritoneal metastases in patients with colorectal cancer: a nationwide study. Eur J Surg Oncol. 2021;47(5):1026–1033. doi: 10.1016/j.ejso.2020.11.135. - DOI - PubMed
    1. Steffen T, Eden J, Bijelic L, et al. Patient selection for hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer: consensus on decision making among international experts. Clin Colorectal Cancer. 2020;19(4):277–284. doi: 10.1016/j.clcc.2020.06.010. - DOI - PubMed
    1. Razenberg LG, Lemmens VE, Verwaal VJ, et al. Challenging the dogma of colorectal peritoneal metastases as an untreatable condition: results of a population-based study. Eur J Cancer. 2016;65:113–120. doi: 10.1016/j.ejca.2016.07.002. - DOI - PubMed

MeSH terms